About Care Access - Tamarac
"Patient Access Location; Research Institute; Alzheimer's Prevention Research"
Clinical Trials at Care Access - Tamarac
During the past decade, Care Access - Tamarac conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Clinical Trials Sponsors and Collaborators
Clinical Trials Conditions at Care Access - Tamarac
According to Clinical.Site data, the most researched conditions in "Care Access - Tamarac" are
"Alzheimer Disease" (1 trials) and "Lipoprotein Disorder" (1 trials). Many other conditions were trialed in "Care Access - Tamarac" in a lesser frequency.
Clinical Trials Intervention Types at Care Access - Tamarac
Most popular intervention types in "Care Access - Tamarac" are "Drug" (2 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (2 trials), "Donanemab" (1 trials) and "LY3819469" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Care Access - Tamarac
The vast majority of trials in "Care Access - Tamarac" are
2 trials for "All" genders.
Clinical Trials Status at Care Access - Tamarac
Currently, there are NaN active trials in "Care Access - Tamarac".
undefined are not yet recruiting,
1 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Care Access - Tamarac,
undefined suspended trials,
and undefined terminated clinical trials to date.
Out of the total trials that were conducted in Care Access - Tamarac, 0 "Phase 1"
clinical trials were conducted, 1 "Phase 2" clinical
trials and 1 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".